Want to join the conversation?
$VRTX 2Q15 Call: Through both geographic and label expansion, Vertex has continued to grow the number of patients treated with KALYDECO, resulting in strong revenue growth. With ORKAMBI approval and launch in US, the company has an even greater opportunity to treat more patients, resulting in additional revenue growth.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?